Arca
Skip to content

Orthostatic hypotension

Drug research and approvals for orthostatic hypotension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 25 studies of orthostatic hypotension are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 25
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 25 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Mar 26, 2026Controlled co2 inhalation to increase blood pressure in neurogenic orthostatic hypotension: a proof-of-concept novel therapy studyCARBON DIOXIDEGOVERNORS OF THE UNIVERSITY OF CALGARYOngoing
Jan 27, 2020A phase 3, 182-week, open-label, safety and tolerability study of td-9855 in treating symptomatic neurogenic orthostatic hypotension (snoh) in subjects with…AMPRELOXETINE (TD-9855)THERAVANCE BIOPHARMA IRELAND LIMITEDClosed
Jun 24, 2019A phase 3, 22-week, multi-center, randomized withdrawal study of td¿9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary…AMPRELOXETINE (TD-9855)THERAVANCE BIOPHARMA IRELAND LIMITEDClosed
Feb 28, 2019A phase 3, 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of td-9855 in treating symptomatic neurogenic orthostatic…AMPRELOXETINE (TD-9855)THERAVANCE BIOPHARMA IRELAND LIMITEDClosed
Dec 11, 2013Phoenix: a clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapyDROXIDOPAChelsea Therapeutics, Inc.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 18, 2014NORTHERATreatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic…Lundbeck LLCApproved
Sep 6, 1996AmatineTreatment of symptomatic orthostatic hypotension.Takeda Development Center Americas, Inc.Approved
May 9, 2023AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophyTheravance Biopharma Ireland LimitedDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.